
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Click the title above to open the Pharmaceutical Technology June 2013 issue in an interactive PDF format.
over 13 years ago
Congress Considers Legislation to Secure Drug Supply Chainover 13 years ago
Q&A with Roberto Darienzo, Halo Pharmaceuticalover 13 years ago
Model-Predictive Design, Control, and Optimizationover 13 years ago
A Lifecycle Approach to Process Validationover 13 years ago
Report from Southeast Asiaover 13 years ago
The Meaning of Metricsover 13 years ago
Product Spotlight: Manufacturing and Equipmentover 13 years ago
Elucidating Heterocyclic Chemistry in Pharmaceuticals




